NCT03661307View on ClinicalTrials.gov

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

DRUG

Quizartinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Daiichi Sankyo

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER